Beleggen.nl
Uitgebreid zoeken
Markt MonitorMarkt Monitor

BioPharma Terug naar discussie overzicht

INSM - Insmed - Deel 15

2.002 Posts
Pagina: «« 1 ... 31 32 33 34 35 ... 101 »» | Laatste | Omlaag ↓
  4. [verwijderd] 25 juni 2007 22:03

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    quote:

    ludwig mack schreef:

    te lang gewacht op de stijging, nu duurder inkopen ..
    Wellicht...Allan die koopt, Glover die komt & Vote over 2 dagen!

    Veel zelfvertrouwen!

    Geluk, F.
  5. ludwig mack 25 juni 2007 22:24

    • ludwig mack

      Lid sinds: 30 jan 2004

      Laatste bezoek: 05 feb 2025

    • Aanbevelingen

      Ontvangen: 412

      Gegeven: 29

    •    Aantal posts: 8.675

    Last Trade: 0.76
    Trade Time: 3:59PM ET
    Change: 0.04 (5.56%)
    Prev Close: 0.72
    Open: 0.80
    Bid: 0.73 x 900
    Ask: 0.77 x 700
    1y Target Est: 2.00

    Day's Range: 0.73 - 0.80
    52wk Range: 0.68 - 1.98
    Volume: 2,667,597
    Avg Vol (3m): 1,875,400
    Market Cap: 77.01M
    P/E (ttm): N/A
    EPS (ttm): -0.53
    Div & Yield: N/A (N/A)

  6. [verwijderd] 26 juni 2007 12:43

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0


    Even ter informatie

    childhood epidemic of blindness"( ROP) in South America June 2007

    Bouzas L, Bauer G, Novali L, Dilger A, Galina L, Falbo J, Díaz González L, Manzitti J, Sola A.

    Area de Neonatología y Seguimiento de Alto Riesgo. Hospital de Pediatría Garrahan. Buenos Aires. Argentina. arquerol@fibertel.com.ar.

    INTRODUCTION: Retinopathy of prematurity (ROP) is the first cause of childhood blindness in Argentina and is reaching epidemic proportions. To gain greater insight into the issues involved in this epidemic, we analyzed the characteristics of the infants referred for treatment of very severe ROP to the Dr. Juan P. Garrahan Pediatric Hospital, located in the city of Buenos Aires. METHODS: We performed a retrospective study of patients referred for ROP from 01/01/96 to 12/31/03. Very severe ROP was defined as threshold disease or worse in both eyes, plus disease in zones 1 or 2, or Rush disease. Unusual patients were defined as those with very severe ROP with a gestational age (GA) of > 31 weeks or birth weight (BW) > 1500 g. Patients were divided into two groups according to the distance between the referring center and our hospital: group A consisted of those from nearby areas (</= 70 km) and group B comprised those from areas > 70 km from the hospital. RESULTS: During the study period, the number of cases progressively increased while the proportion of "unusual" patients slightly decreased. The total number of infants referred was 809 and 14 % were unusual patients; 55 % had very severe ROP, 89 % were treated, and 7 % were referred too late and lost the opportunity for treatment. Group B comprised 61 % of the infants referred. Very severe ROP was present in 53 % of patients in group A and in 56 % of those in group B. The mean GA was 29.5 +/- 3.1 weeks in group A and 30.8 +/- 2.6 in group B (p < 0.001); 90.5 % of the patients in group A and 64 % of those in group B required mechanical ventilation (p < 0.001). No predictors for very severe ROP were found in multifactorial analysis. CONCLUSIONS: We report a childhood epidemic of blindness in which the prevalence of very severe ROP increased during the study period and the disease occurred in large, fairly mature newborns. The differences found in relation to the referring center and the lack of correlation between very severe ROP and prematurity or the use of mechanical ventilation suggests substantial disparity in healthcare, which should be taken into account when planning prevention strategies.


  7. [verwijderd] 26 juni 2007 14:22

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Hieruit blijkt dat Insmed verlopig nog geen goedkeuring had gekregen. Wat mij opvalt is dat ze nooit melding hebben gemaakt van de additionele vragen van CHMP. In ieder geval nog een reden waarom Insmed niet verder wilde gaan met IGFD en een goede leerschool voor de nieuwe indicaties.

    26/06/07 Questions and Answers on the withdrawal of the marketing authorisation application for Iplex

    www.emea.europa.eu/humandocs/Humans/E...

    26/06/07 Withdrawal Assessment Report for Iplex

    www.emea.europa.eu/humandocs/PDFs/EPA...
  8. [verwijderd] 26 juni 2007 15:30

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Insmed Inc. Welcomes Studies Linking IGFBP-3 to Prevention of Blindness in Premature Infants
    Key Protein in Company's Drug IPLEX(TM) is Seen Playing Lead Role in Development of Healthy Eyesight
    RICHMOND, Va., Jun 26, 2007 (BUSINESS WIRE) -- Insmed Incorporated (Nasdaq:INSM), a biopharmaceutical company focused on the development and approval of drugs for the treatment of metabolic diseases with unmet medical needs, today noted the publication of promising results of research from three universities regarding the potential role of insulin-like growth factor binding protein-3 (IGFBP-3) in the prevention of blindness among premature infants.

    IGFBP-3 is a key component of Insmed's lead drug candidate, IPLEX(TM), which has been approved by the U.S. Food and Drug Administration for the treatment of a severe growth disorder and is currently being studied as a treatment for myotonic muscular dystrophy, HIV-associated adipose redistribution syndrome and retinopathy of prematurity (ROP). IPLEX(TM) is the combination of IGFBP-3 with recombinant human insulin-like growth factor 1 (IGF-I).

    The new study results, published in the June 19 issue of the Proceedings of the National Academy of Sciences, focus on the action of IGFBP-3 in promoting normal tissue growth and preventing ROP. Researchers at the University of Florida reported that mice treated with IGFBP-3 showed closer-to-normal growth of retinal vasculature than mice without IGFBP-3 in similar high-oxygen conditions. Researchers at Harvard Medical School and the University of Goteborg in Sweden reported similar results.

    In addition, Harvard Medical School researchers, in collaboration with researchers at the University of Goteborg, reported results of a clinical study showing IGFBP-3 levels in infants with ROP were lower than those of healthy babies. The researchers said these results suggest that IGFBP-3, acting independently of IGF-I, helps prevent oxygen-induced loss of blood-vessels and helps promote vascular re-growth.

    Insmed Chairman and CEO Geoffrey Allan, Ph.D., commented: "These studies by researchers at three distinguished universities mark an important scientific milestone in Insmed's development of IPLEX(TM) as a treatment for ROP. They suggest that IGFBP-3, once thought only to regulate IGF-I, actually plays a broader role in human development and in the growth or regeneration of human tissues. Not only is this discovery important in the fight against ROP, but it also suggests promising avenues for research into the treatment of other conditions associated with ischemia and vascular damage."

  10. [verwijderd] 26 juni 2007 15:36

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    quote:

    Peermanpaapskop schreef:

    Dat geeft de burger moed (en de koers ook trouwens)
    is voorla significatn omdat ze nu EINDELIJK doorHebben dat ze externe onderzoeken wel degelijk als een PR publiekelijk kunnen maken
  12. [verwijderd] 26 juni 2007 16:13

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    quote:

    crackedtooth schreef:

    [quote=Peermanpaapskop]
    Dat geeft de burger moed (en de koers ook trouwens)
    [/quote]

    is voorla significatn omdat ze nu EINDELIJK doorHebben dat ze externe onderzoeken wel degelijk als een PR publiekelijk kunnen maken
    Ja, zouden ze nu eindelijk eens wakker worden?
  19. ludwig mack 26 juni 2007 22:54

    • ludwig mack

      Lid sinds: 30 jan 2004

      Laatste bezoek: 05 feb 2025

    • Aanbevelingen

      Ontvangen: 412

      Gegeven: 29

    •    Aantal posts: 8.675


    Tickliste Zeit Kurs Volumen
    21:59:32 0,7800 390
    21:59:32 0,7800 1000
    21:59:32 0,7800 2510
    21:59:04 0,7100 8699
    21:59:04 0,7700 3019
    21:59:04 0,7710 2000

    die 71 klopt wel / niet; ik heb al dagen een order ligger voor hoger en die is niet gepakt, rara
  20. ludwig mack 27 juni 2007 17:10

    • ludwig mack

      Lid sinds: 30 jan 2004

      Laatste bezoek: 05 feb 2025

    • Aanbevelingen

      Ontvangen: 412

      Gegeven: 29

    •    Aantal posts: 8.675

    Last Trade: 0.80
    Trade Time: 10:53AM ET
    Change: 0.02 (2.33%)
    Prev Close: 0.78
    Open: 0.79
    Bid: 0.80 x 2000
    Ask: 0.80 x 4400
    1y Target Est: 2.00

    Day's Range: 0.78 - 0.80
    52wk Range: 0.68 - 1.98
    Volume: 663,794
    Avg Vol (3m): 1,900,120
    Market Cap: 80.88M
    P/E (ttm): N/A
    EPS (ttm): -0.526
    Div & Yield: N/A (N/A)

2.002 Posts
Pagina: «« 1 ... 31 32 33 34 35 ... 101 »» | Laatste |Omhoog ↑

Direct naar Forum

Zoek alfabetisch op forum

  1. A
  2. B
  3. C
  4. D
  5. E
  6. F
  7. G
  8. H
  9. I
  10. J
  11. K
  12. L
  13. M
  14. N
  15. O
  16. P
  17. Q
  18. R
  19. S
  20. T
  21. U
  22. V
  23. W
  24. X
  25. Y
  26. Z
Forum # Topics # Posts
Aalberts 466 7.001
AB InBev 2 5.481
Abionyx Pharma 2 29
Ablynx 43 13.356
ABN AMRO 1.582 51.192
ABO-Group 1 22
Acacia Pharma 9 24.692
Accell Group 151 4.132
Accentis 2 264
Accsys Technologies 23 10.501
ACCSYS TECHNOLOGIES PLC 218 11.686
Ackermans & van Haaren 1 188
ADMA Biologics 1 34
Adomos 1 126
AdUX 2 457
Adyen 14 17.647
Aedifica 3 901
Aegon 3.258 322.647
AFC Ajax 538 7.086
Affimed NV 2 6.287
ageas 5.844 109.884
Agfa-Gevaert 14 2.048
Ahold 3.538 74.292
Air France - KLM 1.025 34.991
AIRBUS 1 11
Airspray 511 1.258
Akka Technologies 1 18
AkzoNobel 467 13.035
Alfen 16 24.319
Allfunds Group 4 1.468
Almunda Professionals (vh Novisource) 651 4.251
Alpha Pro Tech 1 17
Alphabet Inc. 1 405
Altice 106 51.198
Alumexx ((Voorheen Phelix (voorheen Inverko)) 8.486 114.812
AM 228 684
Amarin Corporation 1 133
Amerikaanse aandelen 3.835 242.709
AMG 971 133.042
AMS 3 73
Amsterdam Commodities 305 6.686
AMT Holding 199 7.047
Anavex Life Sciences Corp 2 482
Antonov 22.632 153.605
Aperam 92 14.900
Apollo Alternative Assets 1 17
Apple 5 380
Arcadis 252 8.731
Arcelor Mittal 2.033 320.549
Archos 1 1
Arcona Property Fund 1 286
arGEN-X 17 10.288
Aroundtown SA 1 219
Arrowhead Research 5 9.715
Ascencio 1 26
ASIT biotech 2 697
ASMI 4.108 39.078
ASML 1.766 105.976
ASR Nederland 21 4.451
ATAI Life Sciences 1 7
Atenor Group 1 469
Athlon Group 121 176
Atrium European Real Estate 2 199
Auplata 1 55
Avantium 32 13.609
Axsome Therapeutics 1 177
Azelis Group 1 64
Azerion 7 3.390